Camp4 Therapeutics Corp

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

CAMP$4.33-7.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibits, Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules

Financial Statements

For a list of the consolidated financial statements and report of Independent Registered Public Accounting Firm (PCAOB ID:42) included herein, see Index to the Consolidated Financial Statements on page 121 of this Annual Report, which is incorporated into this Item by reference.

Exhibits

Exhibit Number	Description of Exhibit	Form	File Number	Date of Filing	Exhibit Number	Filed/Furnished Herewith
3.1	Fifth Amended and Restated Certificate of Incorporation of CAMP4 Therapeutics Corporation	8-K	001-423665	10/15/2024	3.1
3.2	Amended and Restated Bylaws of CAMP4 Therapeutics Corporation	8-K	001-423665	10/15/2024	3.2
4.1	Description of Registered Securities					X
4.2	Third Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated June 3, 2022	S-1	333-282241	9/20/2024	4.1
4.3	Warrant to Purchase Stock, by and between Silicon Valley Bank and CAMP4 Therapeutics Corporation (f/k/a Marauder Therapeutics, Inc.), dated January 4, 2017	S-1	333-282241	9/20/2024	4.2
10.1+	Patent License Agreement by and between CAMP4 Therapeutics Corporation and the Whitehead Institute for Biomedical Research, dated as of October 23, 2019	S-1	333-282241	9/20/2024	10.1
10.2+	First Amendment to Patent License Agreement by and between CAMP4 Therapeutics Corporation and the Whitehead Institute for Biomedical Research, dated as of December 14, 2021	S-1	333-282241	9/20/2024	10.2
10.3+	Second Amendment to Patent License Agreement by and between CAMP4 Therapeutics Corporation and the Whitehead Institute for Biomedical Research, dated as of November 7, 2023	S-1	333-282241	9/20/2024	10.3
10.4#	CAMP4 Therapeutics Corporation Amended and Restated 2016 Stock Option and Grant Plan, as amended, and form of award agreements thereunder	S-1	333-282241	9/20/2024	10.4
10.5#	CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan	S-1/A	333-282241	10/7/2024	10.5
10.6#	Form of Non-Qualified Stock Option Award Agreement for Non-Employee Directors under the 2024 Equity Incentive Plan	S-1/A	333-282241	10/7/2024	10.6
10.7#	Form of Incentive Stock Option Award Agreement under the 2024 Equity Incentive Plan	S-1/A	333-282241	10/7/2024	10.7
10.8#	Form of Non-Qualified Stock Option Award Agreement under the 2024 Equity Incentive Plan	S-1/A	333-282241	10/7/2024	10.8
10.9#	Amended and Restated Employment Agreement by and between CAMP4 Therapeutics Corporation and Josh Mandel-Brehm, dated October 3, 2024	S-1/A	333-282241	10/7/2024	10.9

Exhibit Number	Description of Exhibit	Form	File Number	Date of Filing	Exhibit Number	Filed/Furnished Herewith
10.10#	CAMP4 Therapeutics Corporation 2024 Employee Stock Purchase Plan	S-1/A	333-282241	10/7/2024	10.10
10.11#	Form of Indemnification Agreement between the Registrant and each of its directors and executive officers	S-1/A	333-282241	9/26/2024	10.11
10.12#	CAMP4 Therapeutics Corporation Severance and Change in Control Plan	S-1/A	333-282241	10/7/2024	10.12
10.13#	CAMP4 Therapeutics Corporation Non-Employee Director Compensation Policy	S-1/A	333-282241	10/7/2024	10.13
10.14	Amended Lease agreement by and between CAMP4 Therapeutics Corporation and ARE-MA Region 59, LLC, dated October 3, 2019	S-1	333-282241	9/20/2024	10.14
10.15	Lease by and between CAMP4 Therapeutics Corporation and BCSP Pearl East Property LLC, dated January 3, 2023	S-1	333-282241	9/20/2024	10.15
19.1	Insider Trading Policy					X
21.1	List of Subsidiaries of CAMP4 Therapeutics Corporation	S-1	333-282241	9/20/2024	21.1
23.1	Consent of Ernst & Young LLP, independent registered public accounting firm					X
24.1	Power of Attorney (included on signature page).
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002					X
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002					X
32.1*	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					X
32.2*	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					X
97.1	CAMP4 Therapeutics Corporation Policy for Recoupment of Incentive Compensation	S-1/A	333-282241	10/7/2024	10.16
101.INS	XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document					X
101.SCH	XBRL Taxonomy Extension Calculation Linkbase Document					X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document					X
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document					X
101.LAB	XBRL Taxonomy Extension Label Linkbase Document					X
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document					X
104	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)					X

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.